<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Mazaleuskaya LL</submitter><funding>National Center for Advancing Translational Sciences</funding><funding>Institute for Translational Medicine and Therapeutics</funding><funding>NCATS NIH HHS</funding><funding>NHLBI NIH HHS</funding><funding>National Institutes of Health</funding><funding>Perelman School of Medicine, University of Pennsylvania</funding><pagination>128313</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8484072</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>50</volume><pubmed_abstract>Activated macrophages overexpress the folate receptor β (FR-β) that can be used for targeted delivery of drugs conjugated to folic acid. FR-expressing macrophages contribute to arthritis progression by secreting prostaglandin E&lt;sub>2&lt;/sub> (PGE&lt;sub>2&lt;/sub>). Non-steroidal anti-inflammatory drugs (NSAIDs) block PGs and thromboxane by inhibiting the cyclooxygenase (COX) enzymes and are used for chronic pain and inflammation despite their well-known toxicity. New NSAIDs target an enzyme downstream of COXs, microsomal prostaglandin E synthase-1 (mPGES-1). Inhibition of mPGES-1 in inflammatory macrophages promises to retain NSAID efficacy while limiting toxicity. We conjugated a potent mPGES-1 inhibitor, MK-7285, to folate, but the construct released the drug inefficiently. Folate conjugation t</pubmed_abstract><journal>Bioorganic &amp; medicinal chemistry letters</journal><pubmed_title>Targeted delivery of mPGES-1 inhibitors to macrophages via the folate receptor-β for inflammatory pain.</pubmed_title><pmcid>PMC8484072</pmcid><funding_grant_id>U54 HL117798</funding_grant_id><funding_grant_id>HL117798</funding_grant_id><funding_grant_id>UL1TR001878</funding_grant_id><funding_grant_id>UL1 TR001878</funding_grant_id><pubmed_authors>Lee S</pubmed_authors><pubmed_authors>Mazaleuskaya LL</pubmed_authors><pubmed_authors>Winkler JD</pubmed_authors><pubmed_authors>FitzGerald GA</pubmed_authors><pubmed_authors>Meng H</pubmed_authors></additional><is_claimable>false</is_claimable><name>Targeted delivery of mPGES-1 inhibitors to macrophages via the folate receptor-β for inflammatory pain.</name><description>Activated macrophages overexpress the folate receptor β (FR-β) that can be used for targeted delivery of drugs conjugated to folic acid. FR-expressing macrophages contribute to arthritis progression by secreting prostaglandin E&lt;sub>2&lt;/sub> (PGE&lt;sub>2&lt;/sub>). Non-steroidal anti-inflammatory drugs (NSAIDs) block PGs and thromboxane by inhibiting the cyclooxygenase (COX) enzymes and are used for chronic pain and inflammation despite their well-known toxicity. New NSAIDs target an enzyme downstream of COXs, microsomal prostaglandin E synthase-1 (mPGES-1). Inhibition of mPGES-1 in inflammatory macrophages promises to retain NSAID efficacy while limiting toxicity. We conjugated a potent mPGES-1 inhibitor, MK-7285, to folate, but the construct released the drug inefficiently. Folate conjugation t</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Oct</publication><modification>2025-04-22T12:09:50.855Z</modification><creation>2025-04-06T00:12:58.254Z</creation></dates><accession>S-EPMC8484072</accession><cross_references><pubmed>34390827</pubmed><doi>10.1016/j.bmcl.2021.128313</doi></cross_references></HashMap>